Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy Adakveo, and that ...

Blood cell disorders impair the formation and function of red blood cells, white blood cells, or platelets. Learn more.